---
schema_version: "secwatch.filing_event.v1"
accession: "0001831283-22-000064"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2022-10-12T23:59:59+00:00"
generated_at: "2026-06-23T04:09:27.493340+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# LianBio halts infigratinib CCA program after Helsinn exits US market

## Summary
- Helsinn Healthcare SA permanently discontinues Truseltiq (infigratinib) in US; plans to withdraw NDA for business reasons.
- BridgeBio closing global Phase 3 PROOF-301 trial of infigratinib in first-line cholangiocarcinoma (CCA).
- LianBio terminating all CCA development in China; no longer pursuing infigratinib for CCA in licensed territories.
- LianBio will continue supporting existing patients under the Hainan Named Patient Program.
- LianBio expects to continue Phase 2a trial of infigratinib in gastric cancer and other FGFR-altered solid tumors.

## SEC filing metadata
- accession: 0001831283-22-000064
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2022-10-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000183128322000064/0001831283-22-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000183128322000064/lian-20221012.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831283-22-000064
- JSON: https://secwatch.observer/filing/0001831283-22-000064.json
- Plain text: https://secwatch.observer/filing/0001831283-22-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.